13,514 results match your criteria AIDS[Journal]


Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors.

AIDS 2019 Apr 16. Epub 2019 Apr 16.

Department of Neurology, Washington University in St Louis, St Louis, USA.

Objectives: Neuropsychiatric symptoms have been reported in people living with HIV (PLWH) on integrase strand transfer inhibitors (INSTIs) in post marketing analysis. Limited data exists regarding brain integrity (function and structure) in PLWH prescribed INSTIs compared to other HIV treatment regimens.

Design: A cross-sectional analysis of PLWH on combined antiretroviral therapy (cART) aged >18 years at a single institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002236DOI Listing
April 2019
1 Read

Traditional healers, hiv outcomes, and mortality among people living with hiv in senegal, west africa.

AIDS 2019 Apr 16. Epub 2019 Apr 16.

Department of Medicine, University of Washington, Seattle, WA, USA.

Objectives: The goals of this study were to determine the frequency of traditional healer (TH) use among PLHIV in Senegal, to identify predictors of TH use, and to determine if TH use is associated with HIV outcomes.

Design: Prospective longitudinal study METHODS:: Subjects were enrolled from April 2017-April 2018 in Dakar and Ziguinchor, Senegal. Interviews, clinical evaluations, laboratory analyses, and chart review were conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002232DOI Listing

Clinical significance of elevated liver transaminases in HIV-infected patients.

AIDS 2019 Apr 16. Epub 2019 Apr 16.

McGill University Health Center, Montreal, Quebec, Canada.

: Elevation of liver transaminases is common in patients infected with the Human Immunodeficiency Virus (HIV). Although this is usually an incidental finding during regular work-up, HIV-infected patients with transaminases elevations require additional visits for laboratory studies and clinical assessments, and often undergo interruptions and changes in antiretroviral therapy (ART). Alanine aminotransferase (ALT) is present primarily in the liver, thus being a surrogate marker of hepatocellular injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002233DOI Listing
April 2019
1 Read

Simplifying switch to second line ART: Predicted effect of defining failure of first-line efavirenz-based regimens in sub-Saharan Africa by a single viral load > 1000 copies/ml.

AIDS 2019 Apr 16. Epub 2019 Apr 16.

Institute for Global Health, UCL, London, UK.

Background: Many individuals failing first-line antiretroviral therapy (ART) in sub-Saharan Africa never initiate second-line antiretroviral treatment (ART) or do so after significant delay. For people on ART with a viral load (VL) > 1000 copies/ml, the World Health Organization (WHO) recommends a second VL measurement 3 months after the first VL and enhanced adherence support. Switch to a second-line regimen is contingent upon a persistently elevated VL > 1000 copies/ml. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002234DOI Listing

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe.

AIDS 2019 Apr 16. Epub 2019 Apr 16.

MRC Clinical Trials Unit at UCL, London, UK.

Objectives: A proportion of HIV-infected children with advanced disease develop severe malnutrition soon after antiretroviral therapy (ART) initiation. We tested the hypothesis that systemic inflammation underlies the pathogenesis of severe malnutrition in HIV-infected children.

Design: Cross-sectional laboratory sub-study in 613 HIV-infected children initiating ART in Uganda and Zimbabwe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002231DOI Listing

A strengths-based case management intervention to link HIV-positive PWID in Russia to HIV care - results from a randomized controlled trial.

AIDS 2019 Apr 5. Epub 2019 Apr 5.

First Pavlov State Medical University of St. Petersburg, Lev Tolstoy St. 6/8, St. Petersburg 197022, Russian Federation.

Objective: To determine whether the LINC strengths-based case management intervention was more effective than usual care for linking people who inject drugs (PWID) to HIV care and improving HIV outcomes.

Design: Two-armed randomized controlled trial.

Setting: Participants recruited from a narcology hospital in St. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002230DOI Listing
April 2019
1 Read
5.554 Impact Factor

sST2 levels are not predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression.

AIDS 2019 Apr 3. Epub 2019 Apr 3.

Division of Infectious Diseases, Department of Medicine, University of California San Diego, San Diego, California, United States.

: Before initiation of antiretroviral therapy (ART), levels of sST2 were not elevated in people living with HIV who later developed non-AIDS events (including myocardial infarction and stroke), compared to controls. However, higher sST2 levels measured pre-ART were a significant predictor of death while on ART. Future studies should explore the potential of sST2 to serve as a short-term predictor of non-AIDS events during viral suppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002228DOI Listing
April 2019
2 Reads

Mental health and HIV/AIDS: the need for an integrated response.

AIDS 2019 Apr 17. Epub 2019 Apr 17.

HIV Center for Clinical and Behavioral Studies, NY State Psychiatric Institute and Columbia University, New York, New York.

: Tremendous biomedical advancements in HIV prevention and treatment have led to aspirational efforts to end the HIV epidemic. However, this goal will not be achieved without addressing the significant mental health and substance use problems among people living with HIV (PLWH) and people vulnerable to acquiring HIV. These problems exacerbate the many social and economic barriers to accessing adequate and sustained healthcare, and are among the most challenging barriers to achieving the end of the HIV epidemic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002227DOI Listing
April 2019
2 Reads

Modelling the potential impact of providing pre-exposure prophylaxis (PrEP) in pregnant and breastfeeding women in South Africa.

AIDS 2019 Apr 3. Epub 2019 Apr 3.

Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa.

Objective: HIV-uninfected pregnant and breastfeeding women are at high risk of HIV acquisition, contributing to vertical transmission. Pre-exposure prophylaxis (PrEP) is safe in pregnancy, but PrEP in pregnancy is not policy in many countries including South Africa (SA). We evaluated the potential impact of providing PrEP for pregnant/breastfeeding women using a HIV model for SA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002221DOI Listing
April 2019
4 Reads

Heterogeneity in the costs of medical care among people living with HIV/AIDS in the United States.

AIDS 2019 Apr 3. Epub 2019 Apr 3.

BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 613-1081 Burrard St., Vancouver, BC, Canada V6Z 1Y6.

Objective: The costs of medical care for people with HIV/AIDS (PWH) vary substantially across demographic groups, stages of disease progression and regionally across the US. We aimed to estimate medical costs for PWH and examine the heterogeneity in costs within key patient groups typically distinguished in cost-effectiveness analyses.

Design: Retrospective cohort study using health administrative databases for diagnosed PWH in care at 17 HIV Research Network (HIVRN) sites across the US. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002220DOI Listing
April 2019
2 Reads

Incidence and time trends of anal cancer among people living with HIV in Australia.

AIDS 2019 Apr 3. Epub 2019 Apr 3.

The Kirby Institute, University of New South Wales.

Background: Anal cancer incidence increased markedly in people living with HIV (PLWHIV) after the introduction of highly active antiretroviral therapy, but in a few setting settings, recent declines have been reported. We report the incidence and time trends of anal cancer in PLWHIV in Australia.

Study Design: A data linkage study between the National HIV Registries and the Australian Cancer Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002218DOI Listing
April 2019
4 Reads

Virological response to INSTI-based antiretroviral combinations in HIV-1 group O infected patients.

AIDS 2019 Apr 3. Epub 2019 Apr 3.

Normandie Univ, UNIROUEN, EA2656, GRAM, CHU de Rouen, Laboratoire de Virologie associé au CNR du VIH, F-76000 Rouen, France.

: Whereas integrase strand transfer inhibitors (INSTIs) are widely used in HIV-1 group M (HIV-1/M) infections, little is known about their efficacy against genetically divergent HIV-1 group O (HIV-1/O) strains. Previous phenotypic works have demonstrated the variable susceptibility of HIV-1/O strains, depending on INSTI drugs. Clinical data are very limited and obtained from a few patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002215DOI Listing
April 2019
2 Reads

Correspondence: behavioural changes following HIV seroconversion during the historical expansion of HIV treatment in the United States.

AIDS 2019 May;33(6):1102-1103

Department of Chemical and Biological Engineering, University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002170DOI Listing
May 2019
1 Read

Postzone phenomenon resulting in a false-negative cerebral spinal fluid cryptococcal antigen lateral flow assay.

AIDS 2019 May;33(6):1099-1100

Department of Medicine, Division of Infectious Disease, SUNY Upstate Medical Center, Syracuse, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002157DOI Listing
May 2019
1 Read

Carbamazepine intervention in a patient with efavirenz-induced liver injury.

AIDS 2019 May;33(6):1097-1098

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002116DOI Listing
May 2019
1 Read

Emtricitabine-associated red cell aplasia.

AIDS 2019 May;33(6):1095-1096

Division of Clinical Pharmacology.

: Emtricitabine is structurally similar to lamivudine, which has been associated with red cell aplasia. We describe four patients with severe anaemia presenting soon after starting emtricitabine-containing antiretroviral therapy. Bone marrow biopsy in three patients confirmed red cell aplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002136DOI Listing

Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint.

AIDS 2019 May;33(6):1089-1093

Food and Drug Administration, Center for Drug Evaluation and Research, Office of Antimicrobial Products, Division of Antiviral Products.

: Product labels for cobicistat with atazanavir or darunavir, and for elvitegravir/cobicistat/emtricitabine/tenofovir (alafenamide or disoproxil fumarate) were recently updated to state that these products are not recommended for initiation during pregnancy, and an alternative regimen is recommended for those who become pregnant during therapy with these products. Herein, we present the rationale for these recommendations, which are based on studies in pregnant women evaluating the pharmacokinetics and antiviral activity of darunavir/cobicistat or elvitegravir/cobicistat-containing antiretroviral regimens. In these studies, mean steady-state minimum concentrations in the second and third trimester versus postpartum of cobicistat, darunavir, and elvitegravir were reduced by 61-83%, 89-92%, and 82-86%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002163DOI Listing
May 2019
1 Read

Differences in the rate of nicotine metabolism among smokers with and without HIV.

AIDS 2019 May;33(6):1083-1088

Department of Psychiatry, University of Pennsylvania Perelman School of Medicine.

Objective: HIV-infected smokers lose more life years to tobacco use than to HIV infection. The nicotine metabolite ratio (NMR), a biomarker of CYP2A6, represents individual variation in the rate at which nicotine is metabolized and is associated with response to smoking cessation treatments. We evaluated whether HIV-infected smokers metabolize nicotine faster than HIV-uninfected smokers, which may contribute to the disproportionate smoking burden and may have important treatment implications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457129PMC
May 2019
3 Reads

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.

AIDS 2019 May;33(6):1073-1082

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Background: Scale-up of antiretroviral therapy (ART) and introduction of treat-all strategy necessitates population-level monitoring of acquired HIV drug resistance (ADR) and pretreatment drug resistance (PDR) mutations.

Methods: Blood samples were collected from 4973 HIV-positive individuals residing in 30 communities across Botswana who participated in the Botswana Combination Prevention Project (BCPP) in 2013-2018. HIV sequences were obtained by long-range HIV genotyping. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002166DOI Listing
May 2019
5 Reads

Work and home productivity of people living with HIV in Zambia and South Africa.

AIDS 2019 May;33(6):1063-1071

Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Objective: To compare number of days lost to illness or accessing healthcare for HIV-positive and HIV-negative individuals working in the informal and formal sectors in South Africa and Zambia.

Design: As part of the HPTN 071 (PopART) study, data on adults aged 18-44 years were gathered from cross-sectional surveys of random general population samples in 21 communities in Zambia and South Africa. Data on the number of productive days lost in the last 3 months, laboratory-confirmed HIV status, labour force status, age, ethnicity, education, and recreational drug use was collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002160DOI Listing
May 2019
3 Reads
5.554 Impact Factor

Associations between lipids and subclinical coronary atherosclerosis.

AIDS 2019 May;33(6):1053-1061

Division of Cardiology, Department of Medicine, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine.

Objective: Whether HIV modifies the relationship of serum lipids with coronary atherosclerosis and coronary plaque subtypes is uncertain. We examined the associations between traditional lipids and coronary atherosclerosis among HIV-infected (HIV+) and HIV-uninfected (HIV-) men.

Design: The Multicenter AIDS Cohort Study is an observational cohort with a total of 429 HIV+ and 303 HIV- men who had non-contrast cardiac computed tomography performed to measure coronary artery calcium and coronary computed tomography angiography to measure coronary stenosis, coronary plaque presence, and composition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457132PMC
May 2019
3 Reads

Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection.

AIDS 2019 May;33(6):1043-1052

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.

Objective: To evaluate plasma acylcarnitine profiles and their relationships with progression of carotid artery atherosclerosis among individuals with and without HIV infection.

Design: Prospective cohort studies of 499 HIV-positive and 206 HIV-negative individuals from the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.

Methods: Twenty-four acylcarnitine species were measured in plasma samples of participants at baseline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457128PMC
May 2019
3 Reads

Age-related comorbidities and mortality in people living with HIV in rural Tanzania.

AIDS 2019 May;33(6):1031-1041

Swiss Tropical and Public Health Institute, Basel.

Objective: Causes of morbidity and mortality of people living with HIV are changing with access to antiretroviral therapy and increased life expectancy. Age-related data on comorbidities and their impact on mortality in sub-Saharan Africa are scarce.

Design: This prospective analysis evaluated comorbidities, assessed by means of International Classification of Diseases and Related Health problems 10th revision codes and clinical variables, derived from data collected from the Kilombero & Ulanga antiretroviral cohort of people living with HIV in rural Tanzania. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002171DOI Listing
May 2019
2 Reads

Cardiorespiratory fitness is associated with inflammation and physical activity in HIV+ adults.

AIDS 2019 May;33(6):1023-1030

Division of Cardiovascular Medicine, Case Western Reserve University School of Medicine.

Objective: Our objective was to examine the effect of a lifestyle diet and exercise intervention on cardiorespiratory fitness (CRF) and to examine predictors of change in CRF.

Design: People living with HIV (PLHIV) are at increased risk for cardiovascular disease. CRF is a better predictor of cardiovascular disease-related mortality than established risk factors yet very little is known about CRF in PLHIV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002154DOI Listing
May 2019
3 Reads

Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up.

AIDS 2019 May;33(6):1013-1022

Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine.

Objective: Hepatitis C virus (HCV) treatment may reduce liver-related mortality but with competing risks, other causes of mortality may undermine benefits. We examined changes in cause-specific mortality among HIV-HCV coinfected patients before and after scale-up of HCV treatment.

Design: Prospective multicentre HIV-HCV cohort study in Canada. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002156DOI Listing
May 2019
2 Reads

Distinct gut microbiota profile in antiretroviral therapy-treated perinatally HIV-infected patients associated with cardiac and inflammatory biomarkers.

AIDS 2019 May;33(6):1001-1011

Academic Department of Pediatrics Research Unit of Congenital and Perinatal Infection, Children's Hospital Bambino Gesù.

Objective: Persistent inflammation and higher risk to develop cardiovascular diseases still represent a major complication for HIV-infected patients despite effective antiretroviral therapy (ART). We investigated the correlation between the gut microbiota profile, markers of inflammation, vascular endothelial activation (VEA) and microbial translocation (MT) in perinatally HIV-infected patients (PHIV) under ART.

Design: Cross-sectional study including 61 ART-treated PHIV (age range 3-30 years old) and 71 age-matched healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002131DOI Listing
May 2019
1 Read

Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era.

AIDS 2019 May;33(6):993-1000

INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre Unité d'Hémato-Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France.

Objectives: Epstein-Barr virus (EBV) has been implicated in lymphomagenesis of HIV-related classical Hodgkin lymphoma (HIV-cHL). The utility of EBV molecular and serological biomarkers has scarcely been examined in HIV-cHL in the recent combined antiretroviral therapy (cART) era.

Design: We evaluated EBV DNA load and a panel of EBV antibodies in HIV-cHL patients prospectively enrolled in the French ANRS-CO16 Lymphovir cohort between 2008 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002129DOI Listing
May 2019
1 Read
5.554 Impact Factor

IL-7-induced proliferation of peripheral Th17 cells is impaired in HAART-controlled HIV infection.

AIDS 2019 May;33(6):985-991

The Ottawa Hospital Research Institute, Ottawa.

Objectives: Th17 cells are key regulators of functional immunity in mucosal tissues, including the gut-associated lymphoid tissue (GALT), an important site of immune impairment in HIV infection. During HIV infection, Th17 cells are lost in large numbers from the GALT. Despite the recovery of peripheral CD4 T cells that accompanies suppression of viral replication with HAART, Th17 cells in GALT are not completely restored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002164DOI Listing
May 2019
1 Read

Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders in EcoHIV-infected mice.

AIDS 2019 May;33(6):973-984

Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

Objective: Almost half of HIV-positive people on antiretroviral therapy have demonstrable mild neurocognitive impairment (HIV-NCI), even when virologically suppressed. Intranasal insulin therapy improves cognition in Alzheimer's disease and diabetes. Here we tested intranasal insulin therapy in a model of HIV-NCI in EcoHIV-infected conventional mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002150DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457131PMC
May 2019
3 Reads

Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients.

AIDS 2019 May;33(6):965-972

Laboratory of Retrovirology and Viral Immunopathology, AIDS Research Group, Hospital Clínic- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).

Background: Atripla dose reduction decreases subclinical toxicity and maintains viral suppression in HIV+ individuals but the virological efficacy and immunological safety of this strategy needs to be further confirmed.

Methods: Virologically suppressed HIV-infected adults on Atripla once-daily were randomized 1 : 1 to reduce therapy to 3 days a week (3W, n = 30) or to maintain it unchanged (once-daily, n = 31). HIV-1 reservoir (total and integrated HIV-1 DNA in CD4 cells) and immunological cell activation (CD38 and HLA-DR), senescence (CD57 and CD28), apoptosis (annexinV) as well as T-naive, effector memory (TEM) (CCR7, CD45RA) and stem cell memory (TSCM) (CD954 and CD27) populations were measured at baseline, 24 and 48 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002169DOI Listing
May 2019
3 Reads

Impact of HIV/simian immunodeficiency virus infection and viral proteins on adipose tissue fibrosis and adipogenesis.

AIDS 2019 May;33(6):953-964

Sorbonne Université, INSERM UMR_S938, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Paris.

Objective: HIV-infected patients receiving antiretroviral treatment (ART) often present adipose tissue accumulation and/or redistribution. adipose tissue has been shown to be an HIV/SIV reservoir and viral proteins as Tat or Nef can be released by infected immune cells and exert a bystander effect on adipocytes or precursors. Our aim was to demonstrate that SIV/HIV infection per se could alter adipose tissue structure and/or function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002168DOI Listing
May 2019
1 Read

Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.

AIDS 2019 May;33(6):941-951

Seattle Children's Research Institute.

Objectives: Among women initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based-ART with and without a history of single-dose nevirapine (sdNVP) with or without zidovudine with or without lamivudine (ZDV with and without 3TC) for prevention of mother-to-child HIV transmission (PMTCT), we hypothesized that pre-ART HIV-drug resistance would be associated with virologic failure DESIGN/METHODS:: In a prospectively enrolled study, three genotypic drug-resistance assays [oligonucleotide-ligation-assay (OLA), consensus sequencing, and next-generation sequencing by Illumina] were retrospectively performed to detect pre-ART drug resistance. Minority or majority drug-resistant variants identified in pre-ART RNA and/or DNA, a history of antiretrovirals for PMTCT, and other risk factors were assessed for association with virologic failure.

Results: Failure occurred in 38/169 (22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002134DOI Listing
May 2019
2 Reads

Kidney disease in africans with hiv and tuberculosis.

AIDS 2019 Mar 19. Epub 2019 Mar 19.

King's College London, London, UK.

Objective: To describe the spectrum of kidney disease in African patients with HIV and tuberculosis (TB).

Methods: We used data from three cohorts: consecutive patients with HIV/TB in South London (UK, 2004-2016; n = 95), consecutive patients with HIV/TB who underwent kidney biopsy in Cape Town (South Africa, 2014-2017; n = 70), and consecutive patients found to have HIV/TB on autopsy in Abidjan (Cote d'Ivoire, 1991; n = 100). Acute kidney injury (AKI) was ascertained using the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002204DOI Listing
March 2019
3 Reads

Neuropsychological changes in efavirenz switch regimens in the multicenter AIDS cohort study.

AIDS 2019 Mar 19. Epub 2019 Mar 19.

University of Pittsburgh School of Medicine, Pittsburgh, PA.

Background: Efavirenz is associated with side effects involving the central nervous system. However, it remains largely unknown whether switching off EFV improves neuropsychological performance.

Methods: We utilized data from the Multicenter AIDS Cohort Study (MACS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002206DOI Listing
March 2019
1 Read

Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia.

AIDS 2019 Mar 19. Epub 2019 Mar 19.

Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Objectives: Treatment with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia (PCP) is often associated with adverse effects. Echinocandins, by inhibiting the cyst form of P. jirovecii, may be an alternative therapy for PCP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002207DOI Listing
March 2019
4 Reads

Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.

AIDS 2019 Mar 19. Epub 2019 Mar 19.

Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Fudan University, 130 Dong An Rd., Xuhui District, Shanghai 200032, China.

Objective: To revisit the mechanism of action of enfuvirtide (T20) and based on the newly defined mechanism, design an analogous peptide of T20 with improved antiviral activity.

Design: We compared the inhibitory activity of T20 with that of T1144 on six-helix bundle (6HB) formation at different time after coculture of HIV-1 Env-expressing CHO-Env cells and CD4-expressing MT-2 cells at 31.5°C and with that of T20-SF, an analogous peptide of T20 with an additional tryptophan-rich domain (TRM), on hemolysis mediated by FP-P, which contains fusion peptide (FP) and FP proximal region (FPPR), and HIV-1 infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002208DOI Listing
March 2019
1 Read
5.554 Impact Factor

Dimorphism in the T-cell receptor constant region affects T-cell function, phenotype and HIV outcome.

AIDS 2019 Mar 19. Epub 2019 Mar 19.

Interdisciplinary Program in Medical Microbiology, Graduate School, Chulalongkorn University.

Objectives: CD8 T-cells recognize HLA-peptide complex through the T-cell receptor (TCR). Whilst amino acid variation in TCR variable chains often affects antigen specificity, dimorphism in the beta chain constant region (TRBC1 and TRBC2) is not thought to affect T-cell function. A recent study suggested that adoptive transfer of TRBC1-specific CAR-T cells provided an option for T-cell leukemia therapy that preserved T-cell immunity in the TRBC2 subset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002187DOI Listing

Hearing complaints in HIV infection originate in the brain not the ear.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Muhimbili University School of Health and Allied Sciences, Dar es Salaam, Tanzania.

Objective: Evidence suggests damage to brain auditory pathways, rather than inner ear damage, underlies the hearing difficulties HIV+ individuals report. But, anti-retroviral therapy (ART) may affect the hearing system and also lead to hearing complaints.

Design: Longitudinal study of HIV+ and HIV- individuals in Dar es Salaam Tanzania. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002229DOI Listing
March 2019
1 Read

HIV Incidence during breastfeeding and mother-to-child transmission in cape town, south africa.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Division of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town, South Africa.

: Despite widespread concerns about HIV incidence in pregnant and postpartum women there are few data from Africa on HIV acquisition in breastfeeding and subsequent mother-to-child transmission. We measured HIV incidence in a prospective cohort of 413 peripartum and breastfeeding women who tested HIV-negative during pregnancy. In 377 woman-years accrued postpartum (median duration of follow-up, 1 year) there were 7 women infected after delivery (postpartum incidence, 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002224DOI Listing

Perinatal outcomes associated with maternal HIV and antiretroviral therapy in pregnancies with accurate gestational age in South Africa.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Nuffield Department of Women's & Reproductive Health, University of Oxford, The Women's Centre, John Radcliffe Hospital, Oxford, UK.

Objective: To assess the association of maternal HIV infection and antiretroviral therapy (ART) with perinatal outcomes among women with accurate pregnancy dating and birth weights.

Design: Prospective pregnancy cohort study in Soweto, South Africa.

Methods: Gestational age was estimated by first-trimester ultrasound and birth weight was measured in a standardised manner within 24 hours of birth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002222DOI Listing

The benefit of immediate compared to deferred ART on CD4+ Cell count recovery in early HIV infection.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Objective: To assess the impact of immediate versus deferred antiretroviral therapy (ART) on CD4+ recovery among individuals early in HIV infection.

Design: Using serologic markers of early infection together with self-reported dates of infection and HIV diagnosis, ART-naïve participants who were randomized to immediate versus deferred ART in the Strategic Timing of Antiretroviral Treatment (START) trial were classified into subgroups of duration of HIV infection at baseline. CD4+ cell count recovery over follow-up according to duration of HIV infection was investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002219DOI Listing
March 2019
1 Read
5.554 Impact Factor

Health provider training is associated with improved engagement in HIV care among adolescents and young adults in kenya.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Department of Global Health, University of Washington.

Objectives: Adolescents and young adults (AYA) have poorer retention, viral suppression, and survival than other age groups. We evaluated correlates of initial AYA engagement in HIV care at facilities participating in a randomized trial in Kenya.

Design: Retrospective cohort study METHODS:: Electronic medical records from AYA ages 10-24 attending 24 HIV care facilities in Kenya were abstracted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002217DOI Listing

HIV stigma and viral load among African-American women receiving treatment for HIV: A longitudinal analysis.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Department of Global Health, University of Washington, Ninth and Jefferson Building, 13th Floor, Box 359932, 908 Jefferson Street, Seattle, WA 98104, USA.

Objective: African-American women are more likely than other women in the United States to experience poor HIV-related health; HIV stigma may contribute to these outcomes. This study assessed the relationship between HIV stigma and viral load, over time, among a sample of African-American women receiving treatment for HIV, and explored social support and depressive symptoms as mediators.

Design: Secondary analysis of longitudinal data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002212DOI Listing
March 2019
3 Reads

Effects of 24 Week Toll-Like Receptor 9 Agonist Treatment in HIV-1+ Individuals: a single-arm, phase 1B/2A trial.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Objective: Enhance immune function in HIV-1 infected individuals as a necessary step towards the goal of HIV-1 remission in the absence of combination antiretroviral therapy (cART).

Trial Name And Registration: TEACH: Toll-like receptor 9 Enhancement of Antiviral immunity in Chronic HIV-1 infection: a phase 1b/2a trial; ClinicalTrials.gov NCT02443935. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002213DOI Listing
March 2019
2 Reads

Acceptability and outcomes of distributing HIV self-tests for male partner testing in Kenyan maternal child health and family planning clinics.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Department of Global Health, University of Washington, Seattle, Washington.

Background: Providing HIV self-tests to women for distribution to male partners may provide a unique opportunity to increase male partner and couples testing among women in HIV high-burden settings.

Methods: Between November 2017 and June 2018, we offered self-tests for at-home couples or partner HIV-testing to HIV-uninfected women seeking routine maternal child health (MCH) and family planning (FP) services at 8 facilities in Kisumu, Kenya. Women accepting self-tests were offered ≥2 self-tests (OraQuick) to take to their partner(s) with instructions on use. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002030-900000000-9694
Publisher Site
http://dx.doi.org/10.1097/QAD.0000000000002211DOI Listing
March 2019
5 Reads
5.554 Impact Factor

Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators.

AIDS 2019 03 29. Epub 2019 Mar 29.

Institute for Global Health, UCL, London, UK.

Objective: We aimed to investigate potential causes of higher risk of treatment interruptions within the multi-country START trial in 2015.

Methods: We defined baseline as the date of starting ART and a treatment interruption as discontinuing ART for ≥2 weeks. Participants were stratified by randomisation arm and followed from baseline to earliest of end date of the initial phase of START, death, date of consent withdrawn, or date of first treatment interruption. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002210DOI Listing
March 2019
2 Reads

Allogeneic stem cell transplantation in HIV-1 infected patients with high-risk hematological disorders.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Introduction: Although a number of patients with HIV infection and hematological disease have successfully undergone allogeneic hematopoietic stem cell transplantation (HSCT), short and long-term outcomes remain not well known. We report the largest Spanish experience treating HIV-infected adult patients with high-risk hematological malignancies with allogeneic HSCT.

Methods: We retrospectively reviewed 22 HIV-positive patients who received allogeneic HSCT in 5 centers in Spain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002209DOI Listing
March 2019
2 Reads

Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials.

AIDS 2019 Mar 29. Epub 2019 Mar 29.

Gilead Sciences, Inc., Foster City, CA, USA.

Objective: Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) has been associated with improvement in markers of renal dysfunction in individual randomised trials; however the comparative incidence of clinically significant renal events remains unclear.

Design: We used a pooled data approach to increase the person-years of drug exposure analysed, maximizing our ability to detect differences in clinically significant outcomes.

Methods: We pooled clinical renal safety data across 26 treatment naïve and antiretroviral switch studies in order to compare the incidence of proximal renal tubulopathy (PRT) and discontinuation due to renal adverse events (AEs) between participants taking TAF-containing regimens versus those taking TDF-containing regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002223DOI Listing
March 2019
1 Read